DESIREE MATTHEWS: Open Payments
NPI 1356700561 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$268,698 in 328 payments from 13 companies in 2025. Trend: 2023 $105,492 · 2024 $250,721 · 2025 $268,698
Speaker / faculty: $109,126Consulting: $88,653Travel & lodging: $41,721Honoraria: $22,950Food & beverage: $6,248
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 80 | $61,785 |
| E.R. Squibb & Sons, L.L.C. | 52 | $60,263 |
| Janssen Pharmaceuticals, Inc | 51 | $51,221 |
| Teva Pharmaceuticals USA, Inc. | 39 | $29,046 |
| Axsome Therapeutics, Inc. | 25 | $14,941 |
| Luye Pharma (USA) Ltd. | 9 | $11,523 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $9,643 |
| ABBVIE INC. | 18 | $9,537 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $6,925 |
| Alkermes, Inc. | 8 | $5,249 |
Products named: INGREZZA, INVEGA SUSTENNA, UZEDY, COBENFY, Auvelity, ERZOFRI EXTENDED-RELEASE, CAPLYTA, VRAYLAR.
Industry payments across NC — which companies pay providers there.
